#OrcaBio #allogeneiccelltherapy #OrcaT #Tcelltherapy #investigationalallogeneicTcellimmunotherapy #PrecisionTtrial #acutemyeloidleukaemia #acutelymphoblasticleukaemia #highriskmyelodysplasticsyndrome #mixedphenotypeacuteleukaemia #alloHSCT #cGvHD #alloHSCT
pharmatimes.com/news/orca-bi...
pharmatimes.com/news/orca-bi...
Orca Bio’s T-cell therapy shows promise in haematological malignancies - PharmaTimes
The company is preparing to submit the results to the FDA this year
pharmatimes.com
March 20, 2025 at 12:02 PM
#OrcaBio has become a #commercial-stage company with the #FDA approval of #Tregzi, a #cell-based #immunotherapy designed to prevent graft-versus-host disease (#GvHD) in people who need a #bonemarrowtransplant.
FDA clears Orca's cell therapy Tregzi for GvHD
Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.
buff.ly
July 1, 2026 at 12:15 PM
#OrcaBio has become a #commercial-stage company with the #FDA approval of #Tregzi, a #cell-based #immunotherapy designed to prevent graft-versus-host disease (#GvHD) in people who need a #bonemarrowtransplant.
Funding Raises: #Parloa $350M Series D; #Rain $250M Series C; #OrcaBio $250M Series F; #AirNexisTherapeutics $200M Series A; #HarmattanAI $200M Series B; #JetZero $175M Series B; #Medipost $140M; #Torq $140M; #DefenseUnicorns $136M Series B; #Deepgram $130M Series C
January 16, 2026 at 11:30 PM
Funding Raises: #Parloa $350M Series D; #Rain $250M Series C; #OrcaBio $250M Series F; #AirNexisTherapeutics $200M Series A; #HarmattanAI $200M Series B; #JetZero $175M Series B; #Medipost $140M; #Torq $140M; #DefenseUnicorns $136M Series B; #Deepgram $130M Series C